Literature DB >> 25175796

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

Pierre Peterlin1, Jacques Delaunay1, Thierry Guillaume1, Thomas Gastinne1, Béatrice Mahé1, Viviane Dubruille1, Nicolas Blin1, Amandine Le Bourgeois1, Eolia Brissot1, Laurence Lodé2, Steven Le Gouill3, Philippe Moreau1, Mohamad Mohty1, Patrice Chevallier4.   

Abstract

Double umbilical cord blood (dUCB) allogeneic transplantation after a low-dose total body irradiation, cyclophosphamide, and fludarabine (TCF)-based reduced-intensity conditioning regimen (RIC) is increasingly used in adults lacking a suitable related or unrelated donor. Currently, there are little data regarding the long-term outcome of CD3(+) T cell chimerism (TCC) in this particular setting. Thirty-six adults with various hematological diseases who received dUCB allogeneic transplants conditioned with TCF were included in this retrospective study. Peripheral blood CD3(+) TCC was considered until day +100 after transplantation to determine the impact of full versus mixed chimerism on long-term outcomes. Twenty-nine and 7 patients were documented with full and mixed CD3(+) TCC, respectively, within the first 100 days after transplantation. With a median follow-up of 36 months, 3 year-overall survival (OS), disease-free survival (DFS), and cumulative incidence of relapse (CIR) were 61%, (95% confidence interval [CI], 43% to 75%); 50% (95% CI, 32.5% to 66%), and 28% (95% CI, 16% to 44%), respectively. In univariate analysis, a full CD3(+) TCC was associated with a better 3-year DFS: 59% (95% CI, 39% to 75.5%) versus 14% (95% CI, 7% to 46%); hazard ratio (HR), .24 (.09 to .65); P = .005 and a lower CIR: 24% (95% CI, 21.5% to 57%) versus 78% (95% CI, 52% to 99%); HR, .18 (.05 to .50); P = .004. In multivariate analysis, a full CD3(+) TCC remained associated with a lower CIR (HR, .17 [.028 to .99]; P = .049). CD3(+) TCC has no impact on graft-versus-host disease and nonrelapse mortality in this study. In conclusion, here, full CD3(+) TCC was independently associated with a lower risk of relapse in adults receiving a dUCB TCF RIC allogeneic transplantation. This highlights the need to develop immunotherapy approaches allowing for early conversion to full chimerism after this type of transplantation.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adults; Chimerism; Double cord blood allogeneic stem cells transplantation; Outcomes; RIC; Relapse; TCF conditioning

Mesh:

Substances:

Year:  2014        PMID: 25175796     DOI: 10.1016/j.bbmt.2014.08.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  Use of killer cell immunoglobulin-like receptor genes as early markers of hematopoietic chimerism after double-umbilical cord blood transplantation.

Authors:  Pauline Rettman; Nolwenn Legrand; Catherine Willem; Laurence Lodé; Patrice Chevallier; Anne Cesbron; David Senitzer; Christelle Retière; Katia Gagne
Journal:  Haematologica       Date:  2015-07-23       Impact factor: 9.941

2.  Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Authors:  E Yokohata; Y Kuwatsuka; H Ohashi; S Terakura; N Kawashima; A Seto; S Kurahashi; Y Ozawa; T Goto; N Imahashi; T Nishida; K Miyao; R Sakemura; T Kato; M Sawa; A Kohno; H Sao; H Iida; H Kiyoi; T Naoe; K Miyamura; M Murata
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

3.  Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.

Authors:  Tomoaki Ueda; Tetsuo Maeda; Shinsuke Kusakabe; Jiro Fujita; Kentaro Fukushima; Takafumi Yokota; Hirohiko Shibayama; Yoshiaki Tomiyama; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2018-11-17       Impact factor: 2.490

4.  Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation.

Authors:  Rachael Hough; Andre Lopes; Pip Patrick; Nigel Russell; Kavita Raj; Eleni Tholouli; John A Snowden; Matthew Collin; Nadjet El-Mehidi; Anthony Lawrie; Laura Clifton-Hadley; Paul Veys; Charles Craddock; Stephen Mackinnon; Gordon Cook; Bronwen Shaw; David Marks
Journal:  Blood Adv       Date:  2022-04-12

Review 5.  Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease: Problems and Solutions.

Authors:  Hakan Özdoğu; Can Boğa
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

6.  Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Ying Jiang; Liping Wan; Youwen Qin; Xiaorui Wang; Shike Yan; Kuangcheng Xie; Chun Wang
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

7.  Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Authors:  Christelle Retière; Catherine Willem; Thierry Guillaume; Henri Vié; Laetitia Gautreau-Rolland; Emmanuel Scotet; Xavier Saulquin; Katia Gagne; Marie C Béné; Berthe-Marie Imbert; Beatrice Clemenceau; Pierre Peterlin; Alice Garnier; Patrice Chevallier
Journal:  Oncotarget       Date:  2018-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.